Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.

@article{Christiansen2011EradicationOS,
  title={Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.},
  author={Ailsa J. Christiansen and Alison C. West and Kellie-Marie Banks and Nicole M. Haynes and Michele W. L. Teng and Mark J Smyth and Ricky W. Johnstone},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2011},
  volume={108 10},
  pages={4141-6}
}
Histone deacetylase inhibitors (HDACi) have been successfully used as monotherapies for the treatment of hematological malignancies; however, the single agent effects of HDACi against solid tumors are less robust. Using preclinical models of lymphoma, we have recently demonstrated that HDACi induce tumor cell-specific apoptosis and that this is essential for the therapeutic effects of these agents. Herein, we demonstrate that HDACi can be combined with immune-activating antibodies designed to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Immune in fi ltration in human tumors : a prognostic factor that should not be ignored

  • JB Swann, MJ Smyth
  • Oncogene
  • 2010

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

  • F Ghiringhelli
  • Nat Med
  • 2009

Similar Papers

Loading similar papers…